Director Dennis Langer filed an amended beneficial ownership statement for Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) on October 26, 2026, correcting an inadvertent overstatement of ADS holdings that appeared in an original filing dated August 28, 2026.

Key Highlights

  • Reporting person: Dennis Langer, director of Quoin Pharmaceuticals Ltd.
  • Amendment purpose: The original filing "inadvertently overstated in column 5 the number of shares directly owned by the reporting person following the reported transaction," according to the filing.
  • Corrected ADS balance: 49,687 American Depositary Shares beneficially owned following the reported transaction, held directly.
  • ADS structure: Each ADS represents 35 ordinary shares of the issuer, as disclosed in the filing.
  • Earliest transaction date: August 27, 2026; original filing date: August 28, 2026.
  • Amendment signed: October 26, 2026, by Dennis Langer.

Quoin Pharmaceuticals Director Corrects ADS Count in Amended Disclosure

Dennis Langer, a director at Quoin Pharmaceuticals Ltd., submitted an amended statement of changes in beneficial ownership to correct an error in a prior filing. According to the amended document, the original filing submitted on August 28, 2026 "inadvertently overstated in column 5 the number of shares directly owned by the reporting person following the reported transaction." The amended filing, signed October 26, 2026, replaces the incorrect figure with a corrected total of 49,687 ADSs held directly by Langer.

Quoin Pharmaceuticals is listed on NASDAQ under the ticker QNRX. The company's ordinary shares are represented by American Depositary Shares, with each ADS corresponding to 35 ordinary shares of the issuer, as noted in the filing's explanation of responses. The earliest transaction date associated with the original disclosure was August 27, 2026. No new transactions are reported in the amended filing; the sole purpose stated is the correction of the previously overstated beneficial ownership figure. No derivative securities are listed in Table II of the filing, and no transaction code or price is recorded for the ADS position in Table I, consistent with an amendment focused exclusively on correcting a column 5 entry rather than reporting a new acquisition or disposition.

What Was Disclosed

Director Dennis Langer filed an amended beneficial ownership statement for Quoin Pharmaceuticals Ltd. to correct an overstatement in the original August 28, 2026 filing. The corrected direct ADS holdings total 49,687, with each ADS representing 35 ordinary shares.